Intratumoral CD103⁺CD4⁺ T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients

References

• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet (London, England). 2016 May 10;388(10060):2654–8. doi:10.1016/s0140-6736(16)30354-3.
   PubMed Web of Science ®Google Scholar
• Cheong JH, Yang HK, Kim H, Kim WH, Kim Y-W, Kook M-C, Park Y-K, Kim -H-H, Lee HS, Lee KH, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 2018 Mar 24;19:629–638. doi:10.1016/s1470-2045(18)30108-6.
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005 Apr 28;92:1644–1649. doi:10.1038/sj.bjc.6602573.
   PubMed Web of Science ®Google Scholar
• Nishida T. Adjuvant therapy for gastric cancer after D2 gastrectomy. Lancet (London, England). 2012 Jan 10;379:291–292. doi:10.1016/s0140-6736(11)61928-4.
   PubMed Web of Science ®Google Scholar
• Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010 Apr 23;11:439–449. doi:10.1016/s1470-2045(10)70070-x.
   PubMed Web of Science ®Google Scholar
• Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, Kim -H-H, Choi J-H, Kim H-K, Yu W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Dec 03;15(12):1389–1396. doi:10.1016/s1470-2045(14)70473-5.
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J clin Oncol. 2011 Oct 20;29(33):4387–4393. doi:10.1200/jco.2011.36.5908.
   PubMed Web of Science ®Google Scholar
• Tsujimoto H, Ono S, Ichikura T, Matsumoto Y, Yamamoto J, Hase K. Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes? Gastric Cancer. 2010 Dec 04;13:212–221. doi:10.1007/s10120-010-0568-x.
   PubMed Web of Science ®Google Scholar
• Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014 Aug 29;345(2):196–202. doi:10.1016/j.canlet.2013.08.016.
   PubMed Web of Science ®Google Scholar
• Yolanda LV, Sergio PD, Hugo ES, Isabel AFR, Rafael B-Z, Aldo T-D, Gonzalo C-R. Gastric cancer progression associated with local humoral immune responses. BMC Cancer. 2015 Nov 22;15:924. doi:10.1186/s12885-015-1858-9.
   PubMed Web of Science ®Google Scholar
• Luckheeram RV, Zhou R, Verma AD, Xia B. CD4 + T cells: differentiation and functions. Clin Dev Immunol. 2012 Apr 05;2012:925135. doi:10.1155/2012/925135.
   PubMedGoogle Scholar
• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008 Aug 30;112:1557–1569. doi:10.1182/blood-2008-05-078154.
   PubMed Web of Science ®Google Scholar
• Colantonio L, Recalde H, Sinigaglia F, D’Ambrosio D. Modulation of chemokine receptor expression and chemotactic responsiveness during differentiation of human naive T cells into Th1 or Th2 cells. Eur J Immunol. 2002 May 01;32(5):1264–1273. doi:10.1002/1521-4141(200205)32:5<1264::Aid-immu1264>3.0.Co;2-s.
   PubMed Web of Science ®Google Scholar
• Read KA, Powell MD, Sreekumar BK, Oestreich KJ. In vitro differentiation of effector CD4(+) T helper cell subsets. Methods Mol Biol (Clifton, NJ). 2019 Feb 25;1960:75–84. doi:10.1007/978-1-4939-9167-9_6.
   PubMedGoogle Scholar
• Boutet M, Gauthier L, Leclerc M, Gros G, de Montpreville V, Théret N, Donnadieu E, Mami-Chouaib F. TGFbeta signaling intersects with CD103 integrin signaling to promote T-Lymphocyte Accumulation and antitumor activity in the lung tumor microenvironment. Cancer Res. 2016 Feb 28;76:1757–1769. doi:10.1158/0008-5472.Can-15-1545.
   PubMed Web of Science ®Google Scholar
• Li R, Liu H, Cao Y, Wang J, Chen Y, Qi Y, Lv K, Liu X, Yu K, Lin C, et al. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103(+)CD8(+) T cells conferring favourable prognosis. Br J Cancer. 2020 Mar 25. doi:10.1038/s41416-020-0813-y.
   Web of Science ®Google Scholar
• Klicznik MM, Morawski PA, Hollbacher B, Varkhande SR, Motley SJ, Kuri-Cervantes L, Goodwin E, Rosenblum MD, Long SA, Brachtl G, et al. Human CD4 + CD103 + cutaneous resident memory T cells are found in the circulation of healthy individuals. Sci Immunol. 2019 Jul 07;4(37):eaav8995. doi:10.1126/sciimmunol.aav8995.
   PubMed Web of Science ®Google Scholar
• Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Wang T, et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019 Oct 09;75(5):752–763. doi:10.1016/j.eururo.2018.09.030.
   PubMed Web of Science ®Google Scholar
• Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011 Aug 19;71(17):5670–5677. doi:10.1158/0008-5472.Can-11-0268.
   PubMed Web of Science ®Google Scholar
• Konig L, Mairinger FD, Hoffmann O, Bittner A-K, Schmid KW, Kimmig R, Kasimir-Bauer S, Bankfalvi A. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. BMC Cancer. 2019 Feb 06;19(1):120. doi:10.1186/s12885-019-5320-2.
   PubMed Web of Science ®Google Scholar
• Wang JT, Li H, Zhang H, Chen YF, Cao YF, Li RC, Lin C, Wei YC, Xiang XN, Fang HJ, et al. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2019 Nov 18;30(2):266–273. doi:10.1093/annonc/mdy505.
   PubMed Web of Science ®Google Scholar
• Guery L, Hugues S. Th17 cell plasticity and functions in cancer immunity. Biomed Res Int. 2015 Nov 20;2015:314620. doi:10.1155/2015/314620.
   PubMed Web of Science ®Google Scholar
• Lee GR. The balance of Th17 versus treg cells in autoimmunity. Int J Mol Sci. 2018 Mar 08;19. doi:10.3390/ijms19030730.
   Web of Science ®Google Scholar
• Muller A, Schott-Ohly P, Dohle C, Gleichmann H. Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology. 2002 May 10;205:35–50. doi:10.1078/0171-2985-00109.
   PubMed Web of Science ®Google Scholar
• Liu X, Cao Y, Li R, Gu Y, Chen Y, Qi Y, Lv K, Wang J, Yu K, Lin C, et al. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer. Eur J Cancer (Oxford, England: 1990). 2020 Feb 29;128:27–37. doi:10.1016/j.ejca.2020.01.002.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J, Sun Y. Tumor-infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018 Oct 21;267(2):311–318. doi:10.1097/sla.0000000000002058.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Kim YW, Yang HK, Chung HC, Park Y-K, Lee KH, Lee K-W, Kim YH, Noh S-I, Cho JY, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012 Jan 10;379:315–321. doi:10.1016/s0140-6736(11)61873-4.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xie J, Han Z, Liu W, Xi S, Huang L, Huang W, Lin T, Zhao L, Hu Y, et al. Immunomarker support vector machine classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefit. Clin Cancer Res. 2018 Jul 26;24(22):5574–5584. doi:10.1158/1078-0432.Ccr-18-0848.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003 May 02;3:330–338. doi:10.1038/nrc1074.
   PubMed Web of Science ®Google Scholar